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Over the last several years demonstration of cell line clonality has been a topic of many
industry and regulatory presentations and papers. The rationale behind characterizing
clonality stems from the expectation that bioprocesses must produce a consistent biologic.
A clonally-derived cell line should help ensure a consistent product profile. However,
increased attention on this aspect of cell line development has resulted in industry
questioning of the relative importance of clonality in the larger context of product quality
and process consistency testing (Frye et al., 2016). It is the position of the current authors
that assurance of a consistent biologic is best addressed by the totality of data including
process and product consistency, as monoclonality is only one portion of the entire control
strategy. Though debate continues on the relevance of a clonal population to the consistency
of a product, many have implemented procedures and technology intended to achieve
acceptable assurance of clonality for products entering clinical development today. This
move has strengthened the industry as a whole, but many sponsors still face a challenge
with older cell lines created in a manner that did not meet the current set definition of
clonality, which we refer to as “legacy cell lines” in this article. In this poster we, members
of the IQ Consortium working group on clonality, present our position on genetic testing of
legacy cell lines to characterize clonal origin, methods that could be useful for genetic
analysis, and case studies that highlight the pros and cons of such testing in light of its
relative importance to regulatory filings for biologics production.
Summary
Introduction and Team Position
We propose the purpose of performing additional assurance experiments to demonstrate monoclonal
origin should be eliminating the need for additional process control. This position, we feel, needs to be
clearly addressed by regulatory authorities so that the supplemental work is not done in vain.
Conclusion
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Regulatory guidance (ICH Q5D) instructs cloning the cell substrate “from a single cell progenitor”
during cell line development. Presentations from FDA colleagues and industry experience over the last
several years have established an expectation for sponsors to provide high assurance of clonality
(Kennett, 2014; Novak, 2017; Welch, 2017). The FDA has recommended that two-rounds of limiting
dilution cloning (LDC) at sufficiently low seeding densities (≤0.5 cells/well) provides acceptable
probability that a cell line is clonal. More recently, one-round of cloning through FACS or LDC with
sufficient supporting justification, such as use of imaging technology, has provided acceptable assurance
of clonality when using validated methods. However, some ongoing clinical programs employ legacy
cell lines that were created before the industry had such practices and methods in place, and may not
satisfy current regulatory expectations for clonality.
The choice of if or when to implement additional work to provide supplemental assurance of clonality is
something each sponsor must evaluate individually based on available process and product data, product
stage, and individual experience. The typical stages in which data are obtained for justifying that a cell
line is appropriate for commercial production are provided in Figure 1. Ultimately, the BLA will include
data from extensive process characterization studies performed to demonstrate consistent product quality
and cell culture performance from qualified scale-down, pilot and commercial scales, as well as cell line
genetic characterization studies to show stable transgene integration profiles. These data should suffice
for approval, but are typically not available until late in product development and present challenges
during earlier clinical development stages to properly mitigate filing risk associated with a putative non-
clonal bank.
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Providing Assurance of Clonality for Legacy Cell Lines
Figure 1. Typical Approach to Supporting Clonality
Figure 2: Decision tree for 
implementing additional genetic 
testing as assurance of clonality
The ultimate requirement for all 
commercial cell lines, regardless of 
Cell line Development history, is 
demonstration of consistent process 
performance and product quality 
during process characterization 
(Process Control) and conformance 
(Assurance). These data are not 
typically available at early clinical 
stage to support the consistency of 
legacy cell lines. As such, some legacy 
cell lines may receive IND non-hold 
questions regarding clonality and a 
request to provide additional assurance 
of clonal origin (Additional 
Assurance). The authors propose that 
if additional genetic testing is 
performed and provides assurance of 
clonal origin then no further proof of 
clonality should be required (dark grey 
YES arrow).
If genetic testing does not support clonality or is inconclusive then augmented control strategies may be
required (dark grey NO arrow), depending on the totality of data, including product quality, process
performance and stability. Sponsors may choose not to perform additional genetic tests (dashed arrows),
opting to 1) proceed with standard process control strategies or, based on project status, 2) implement
augmented control strategies. The expectations at this decision junction need further elucidation from
health authorities as some authors have experienced requests for augmented control strategies in addition
to genetic testing that could demonstrate cell line clonality.
The FDA has indicated a willingness to accept different types of genetic data as additional assurance of
clonality, including characterizing individual subclones from the MCB (Welch, 2017). A number of
innovative technologies and approaches to providing additional assurance of clonality are presented in
this article. Although new technologies provide an ability to analyze a cell line’s genetic profile in detail,
the consensus of these authors is that acceptance of these approaches by regulatory agencies is still
unknown. This uncertainty is outlined conceptually in Figure 2, showing an example approach to provide
additional assurance of clonality that could avoid a request for implementing additional process controls.
However, it is the experience of some of the authors that providing additional assurance of clonality has
not been acceptable to preclude the requirement for augmented control strategy, even when consistent
genetic profiles indicate a monoclonal cell origin.
Method Primary Clone Analytical Subclones 
Southern 
Blot 
Traditionally used to compare MCB to 
EOP cells. Accepted methodology for BLA 
filing. 
A single shared hybridization band in a 
suitable number of analytical subclones can 
provide assurance of clonal origin.  
FISH 
Karyotype analysis of individual cells from 
the MCB can identify unique, consistent 
integration sites to support clonal origin. 
Not necessary as integration site consistency 
can be detected in MCB. 
Next 
Generation 
Sequencing 
Whole genome sequencing and Targeted 
Locus Amplification can provide detailed 
transgene and integration site DNA 
sequence.  
TLA provides greater sequence coverage 
of the targeted transgene and flanking 
genome and can detect low frequency 
gene of interest sequence variants. 
RNAseq can be used to validate low level 
sequence variants. 
Unique transgene integration sites or 
sequence variant markers can be used as 
clone-specific markers for subsequent PCR-
based assays.  
Markers identified in a suitable number of 
analytical subclones can provide assurance 
of clonal origin. These NGS methods could 
be performed directly on analytical 
subclones but are data and cost intensive 
compared to PCR-based assays. 
PCR 
Inverse and Splinkerette PCR can be used 
to identify transgene genomic integration 
fusion junctions and flanking sequences. 
Genomic integration site junctions are 
unique identifiers that can be used for 
comparing a suitable number of analytical 
subclones to provide assurance of clonal 
origin. 
 
Optional Genetic Testing as Assurance for Clonality
References
We recognize that additional assurance studies do not fully mitigate risk, as genetic demonstration of
clonal origin does not ensure process consistency and, conversely, non-clonal cell lines can produce
consistent process/product. It is important to highlight that no one genetic technique is sufficient to
demonstrate clonality conclusively due to the plasticity of the CHO cells and high rate of genetic drift.
They at best provide the supporting data that the cell line was clonally-derived. The methods described
herein can be useful for supporting monoclonal origin, but can also reveal genetic inconsistencies that
are not easily explained. Thus, the proposed methods are useful if they provide assurance of
monoclonality, and can strengthen regulatory filings, but may not change the course of development if
they do not provide clear assurance of clonality, depending on demonstration of process consistency.
